Search

Your search keyword '"Schubert, Maria-Luisa"' showing total 16 results
Start Over Author "Schubert, Maria-Luisa" Publisher american society of hematology
16 results on '"Schubert, Maria-Luisa"'

1. Extracorporeal photopheresis as a promising strategy for the treatment of GvHD after CAR-T cell therapy

Author

Han, Huixiu, primary, Wang, Lei, additional, Ding, Yuntian, additional, Neuber, Brigitte, additional, Hueckelhoven-Krauss, Angela Gabriele, additional, Lin, Min, additional, Yao, Hao, additional, Chen, Qian, additional, Sauer, Tim, additional, Schubert, Maria-Luisa, additional, Guo, Zhiqiang, additional, Müller-Tidow, Carsten, additional, Schmitt, Michael, additional, and Schmitt, Anita, additional

Published
2024
Full Text
View/download PDF

2. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

Author

Schubert, Maria-Luisa, primary, Bethge, Wolfgang A., additional, Ayuk, Francis A., additional, von Bonin, Malte, additional, Vucinic, Vladan, additional, Wagner-Drouet, Eva Marie, additional, Subklewe, Marion, additional, Baldus, Claudia D., additional, Glass, Bertram, additional, Marks, Reinhard, additional, Mougiakakos, Dimitrios, additional, Schroers, Roland, additional, Stelljes, Matthias, additional, Topp, Max S., additional, Wulf, Gerald, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2023
Full Text
View/download PDF

3. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Author

Rejeski, Kai, primary, Subklewe, Marion, additional, Aljurf, Mahmoud, additional, Bachy, Emmanuel, additional, Balduzzi, Adriana, additional, Barba, Pere, additional, Bruno, Benedetto, additional, Benjamin, Reuben, additional, Carrabba, Matteo G., additional, Chabannon, Christian, additional, Ciceri, Fabio, additional, Corradini, Paolo, additional, Delgado, Julio, additional, Di Blasi, Roberta, additional, Greco, Raffaella, additional, Houot, Roch, additional, Iacoboni, Gloria, additional, Jäger, Ulrich, additional, Kersten, Marie José, additional, Mielke, Stephan, additional, Nagler, Arnon, additional, Onida, Francesco, additional, Peric, Zinaida, additional, Roddie, Claire, additional, Ruggeri, Annalisa, additional, Sánchez-Guijo, Fermín, additional, Sánchez-Ortega, Isabel, additional, Schneidawind, Dominik, additional, Schubert, Maria-Luisa, additional, Snowden, John A., additional, Thieblemont, Catherine, additional, Topp, Max, additional, Zinzani, Pier Luigi, additional, Gribben, John G., additional, Bonini, Chiara, additional, Sureda, Anna, additional, and Yakoub-Agha, Ibrahim, additional

Published
2023
Full Text
View/download PDF

4. Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Author

Dreger, Peter, primary, Schubert, Maria-Luisa, additional, Holtick, Udo, additional, Subklewe, Marion, additional, Bastian, von Tresckow, additional, Ayuk, Francis A., additional, Wagner, Eva Maria, additional, Wulf, Gerald, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, Von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D., additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max, additional, Wolff, Daniel, additional, Schroers, Roland, additional, Borchmann, Peter, additional, Rejeski, Kai, additional, Hanoun, Christine, additional, Lengerke, Claudia, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Kröger, Nicolaus, additional, and Bethge, Wolfgang A, additional

Published
2021
Full Text
View/download PDF

5. Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Author

Schubert, Maria-Luisa, primary, Schmitt, Anita, additional, Neuber, Brigitte, additional, Hückelhoven-Krauss, Angela, additional, Kunz, Alexander, additional, Wang, Lei, additional, Michels, Birgit, additional, Waldhoff, Philip, additional, Sellner, Leopold, additional, Korell, Felix, additional, Hofmann, Susanne, additional, Pavel, Petra, additional, Ho, Anthony D, additional, Müller-Tidow, Carsten, additional, Dreger, Peter, additional, and Schmitt, Michael, additional

Published
2021
Full Text
View/download PDF

6. CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR

Author

Schanda, Nicola, primary, Kunz, Alexander, additional, Sauer, Tim, additional, Schubert, Maria-Luisa, additional, Korell, Felix, additional, Hückelhoven-Krauss, Angela, additional, Neuber, Brigitte, additional, Hinkelbein, Mandy, additional, Müller-Tidow, Carsten, additional, Schmitt, Michael, additional, and Schmitt, Anita, additional

Published
2021
Full Text
View/download PDF

9. Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)

Author

Ding, Yuntian, primary, Wang, Lei, additional, Ni, Ming, additional, Gong, Wenjie, additional, Wang, Sanmei, additional, Neuber, Brigitte, additional, Schubert, Maria-Luisa, additional, Sauer, Tim, additional, Hückelhoven-Krauss, Angela, additional, Luft, Thomas, additional, Hegenbart, Ute, additional, Schönland, Stefan, additional, Eckstein, Volker, additional, Wang, Jishi, additional, Krüger, William Hermann, additional, Müller-Tidow, Carsten, additional, Dreger, Peter, additional, Schmitt, Michael, additional, and Schmitt, Anita, additional

Published
2021
Full Text
View/download PDF

10. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Author

Dreger, Peter, primary, Dietrich, Sascha, additional, Schubert, Maria-Luisa, additional, Selberg, Lorenz, additional, Bondong, Andrea, additional, Wegner, Mandy, additional, Stadtherr, Peter, additional, Kimmich, Christoph, additional, Kosely, Florentina, additional, Schmitt, Anita, additional, Pavel, Petra, additional, Liebers, Nora, additional, Luft, Thomas, additional, Hegenbart, Ute, additional, Radujkovic, Aleksandar, additional, Ho, Anthony Dick, additional, Müller-Tidow, Carsten, additional, and Schmitt, Michael, additional

Published
2020
Full Text
View/download PDF

11. Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Author

Blumenberg, Viktoria, primary, Schubert, Maria-Luisa, additional, Zamir, Eli, additional, Schmidt, Sabine, additional, Rohrbach, Roman, additional, Waldhoff, Philipp, additional, Bozic, Daria, additional, Pock, Hendrik, additional, Elinav, Eran, additional, Schmidt, Christian, additional, Buecklein, Veit, additional, Müller-Tidow, Carsten, additional, Dreger, Peter, additional, von Bergwelt, Michael, additional, Schmitt, Michael, additional, Subklewe, Marion, additional, and Stein-Thöringer, Christoph, additional

Published
2020
Full Text
View/download PDF

12. Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Author

Schubert, Maria-Luisa, primary, Schmitt, Anita, primary, Neuber, Brigitte, primary, Hückelhoven-Krauss, Angela, primary, Kunz, Alexander, primary, Wang, Lei, primary, Gern, Ulrike, primary, Michels, Birgit, primary, Sellner, Leopold, primary, Hofmann, Susanne, primary, Müller-Tidow, Carsten, primary, Dreger, Peter, primary, and Schmitt, Michael, primary

Published
2019
Full Text
View/download PDF

14. The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Author

Yang, Mingya, primary, Wang, Lei, additional, Ni, Ming, additional, Schubert, Maria-Luisa, additional, Neuber, Brigitte, additional, Hückelhoven-Krauss, Angela, additional, Gößmann, Ruben A., additional, Kleist, Christian, additional, Eckstein, Volker, additional, Müller-Tidow, Carsten, additional, Dreger, Peter, additional, Schmitt, Michael, additional, and Schmitt, Anita, additional

Published
2019
Full Text
View/download PDF

15. Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells

Author

Hoffmann, Jean-Marc, primary, Wang, Lei, additional, Hückelhoven, Angela, additional, Schmitt, Anita, additional, Gern, Ulrike, additional, Sellner, Leopold, additional, Kleist, Christian, additional, Wenthe, Jessica, additional, Wuchter, Patrick, additional, Schubert, Maria-Luisa, additional, Yoo, Hyeon Joo, additional, Ni, Ming, additional, Hofmann, Susanne, additional, Dreger, Peter, additional, Ho, Anthony D., additional, Loskog, Angelica, additional, and Schmitt, Michael, additional

Published
2016
Full Text
View/download PDF

16. Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy.

Author

Han H, Wang L, Ding Y, Neuber B, Hückelhoven-Krauss A, Lin M, Yao H, Chen Q, Sauer T, Schubert ML, Guo Z, Müller-Tidow C, Schmitt M, and Schmitt A

Subjects
Humans, Receptors, Chimeric Antigen, T-Lymphocytes immunology, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Graft vs Host Disease therapy, Graft vs Host Disease etiology, Photopheresis methods, Immunotherapy, Adoptive methods, Immunotherapy, Adoptive adverse effects
Abstract

Abstract: Graft-versus-host disease (GVHD) occurs in about 10% to 33% of patients receiving "allogeneic" or "autologous" chimeric antigen receptor T (CAR-T) cells after preceding allogeneic hematopoietic stem cell transplantation (allo-HSCT) due to the substantial presence of alloreactive T cells. Extracorporeal photopheresis (ECP) shows promising clinical outcomes in the treatment of GVHD after allo-HSCT without hampering antitumor and antiviral effects. This raises an interesting question: whether ECP might constitute a new way to treat patients with GVHD after CAR T-cell therapy without compromising CAR-T cells significantly. Third-generation CD19-specific CAR-T cells were generated and an in vitro ECP protocol was established. The impact of ECP on CAR-T cells was comprehensively investigated in 2 models: the nondilution model reflects days after CAR T-cell infusion and the dilution model weeks after infusion. The therapeutic effect of ECP on GVHD was examined in an in vitro mixed lymphocyte reaction (MLR) assay. We found, ECP-treated CAR-T cells demonstrated reduced potency in inducing alloreaction compared with that of the group without ECP treatment in MLR assay. ECP could selectively induce apoptosis, thereby enriching the naive and central memory CAR-T cells with a reduced alloreactivity. The cytokine milieu of CAR-T cells could be switched from immune stimulation to immune tolerance in both models. Moreover, ECP could modulate the proliferative capacity of CAR-T cells without hampering their long-term functionality in the dilution model. In conclusion, ECP constitutes a promising treatment strategy for GVHD after allo-HSCT and CAR T-cell transfusion, as ECP reduces the alloreactivity without hampering CAR T-cell functionality., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results